Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively ...
Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of ...
NGNE to update on a potential registrational phase 3 study, using NGN-401, for the treatment of patients with Rett Syndrome.
Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study ...
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODILâ„¢, evaluating the safety, tolerability and exploratory efficacy of ...
Biomed Industries, Inc. Biomed pipeline Biomed Industries, Inc. to Announce Phase 2/3 Results of NA-921 for the Treatment of Rett Sy ...
Axiomerâ„¢ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for ...
Preliminary data presented at the 2024 Rett Syndrome Scientific meeting demonstrated safety and consistent improvements across clinical domains for Rett syndrome symptoms. This early success has ...